| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) | RFA-CA-25-007 | 03/04/2025 | 10/04/2025 | P50 |
| Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) | RFA-CA-25-006 | 03/04/2025 | 10/04/2025 | U01 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) | RFA-CA-25-005 | 03/04/2025 | 10/04/2025 | R01 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-25-004 | 03/04/2025 | 10/04/2025 | R33 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | RFA-CA-25-003 | 03/04/2025 | 10/04/2025 | R61 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-25-002 | 03/04/2025 | 10/04/2025 | R33 |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | RFA-CA-25-001 | 03/04/2025 | 10/04/2025 | R61 |
| Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed) | PAR-25-119 | 01/14/2025 | 10/24/2025 | U01 |
| Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed) | PAR-25-118 | 01/14/2025 | 10/24/2025 | UH2 |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) | PAR-25-044 | 01/16/2025 | 01/08/2028 | R21 |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | PAR-25-043 | 01/05/2025 | 01/08/2028 | R01 |
| Notice of Special Interest: Women’s Health Research | NOT-OD-24-079 | 03/26/2024 | 09/09/2025 | N/A |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | 11/04/2024 | 12/05/2026 | R50 |
| Notice of Special Interest (NOSI): Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy | NOT-CA-24-055 | 07/11/2024 | 09/09/2025 | N/A |
| Support for Research Excellence – First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed) | PAR-25-415 | 08/09/2025 | 09/08/2028 | R16 |
| Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed) | PAR-25-414 | 08/29/2025 | 09/08/2028 | R16 |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | PAR-24-311 | 01/05/2025 | 01/08/2028 | R01 |
| Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) | NOT-CA-24-016 | 12/05/2023 | 09/09/2025 | R21 |
| Notice of Special Interest (NOSI): Research Projects to Develop Oncoaging Models for Cancer Research | NOT-CA-23-092 | 10/16/2023 | 09/09/2025 | N/A |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | PAR-24-306 | 01/05/2025 | 09/08/2026 | R01 |
| Notice of Special Interest (NOSI): Research on HIV-associated Malignancies | NOT-CA-23-070 | 06/08/2023 | 09/09/2025 | N/A |
| Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology | NOT-CA-23-060 | 04/17/2023 | 09/09/2025 | N/A |
| Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications | NOT-EB-23-002 | 04/14/2023 | 09/09/2025 | N/A |
| Biology of Bladder Cancer (R01 Clinical Trial Optional) | PAR-25-129 | 01/05/2025 | 09/08/2025 | R01 |
| Biology of Bladder Cancer (R21 Clinical Trial Optional) | PAR-25-128 | 01/16/2025 | 09/08/2025 | R21 |
| Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer | NOT-CA-22-085 | 05/05/2022 | 09/09/2025 | N/A |
| Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed) | PAR-25-214 | 01/15/2025 | 01/08/2026 | R21 |
